Germline TP53 Variants and Susceptibility to Osteosarcoma

被引:79
|
作者
Mirabello, Lisa [1 ]
Yeager, Meredith [2 ]
Mai, Phuong L. [1 ]
Gastier-Foster, Julie M. [3 ,4 ]
Gorlick, Richard [5 ]
Khanna, Chand [6 ]
Patino-Garcia, Ana [7 ]
Sierrasesumaga, Luis [7 ]
Lecanda, Fernando [7 ]
Andrulis, Irene L. [8 ]
Wunder, Jay S. [8 ]
Gokgoz, Nalan [8 ]
Barkauskas, Donald A. [9 ]
Zhang, Xijun [2 ]
Vogt, Aurelie [2 ]
Jones, Kristine [2 ]
Boland, Joseph F. [2 ]
Chanock, Stephen J. [1 ]
Savage, Sharon A. [1 ]
机构
[1] NCI, Div Canc Epidemiol & Genet, NIH, US Dept HHS, Bethesda, MD 20850 USA
[2] Frederick Natl Lab Canc Res, Canc Genom Res Lab, Leidos Biomed Res, Frederick, MD USA
[3] Nationwide Childrens Hosp, Columbus, OH USA
[4] Ohio State Univ, Dept Pathol & Pediat, Columbus, OH 43210 USA
[5] Childrens Hosp Montefiore, Albert Einstein Coll Med, Bronx, NY USA
[6] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[7] Univ Navarra, Dept Pediat, Univ Navarra Clin, E-31080 Pamplona, Spain
[8] Univ Toronto, Mt Sinai Hosp, Litwin Ctr Canc Genet, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada
[9] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
TUMOR-SUPPRESSOR GENE; LI-FRAUMENI SYNDROME; BREAST-CANCER; P53; MUTATIONS; CHILDREN; FAMILY; RHABDOMYOSARCOMA; SURVEILLANCE; PATTERNS; SURVIVAL;
D O I
10.1093/jnci/djv101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The etiologic contribution of germline genetic variation to sporadic osteosarcoma is not well understood. Osteosarcoma is a sentinel cancer of Li-Fraumeni syndrome (LFS), in which approximately 70% of families meeting the classic criteria have germline TP53 mutations. We sequenced TP53 exons in 765 osteosarcoma cases. Data were analyzed with chi(2) tests, logistic regression, and Cox proportional hazards regression models. We observed a high frequency of young osteosarcoma cases (age <30 years) carrying a known LFS- or likely LFS-associated mutation (3.8%) or rare exonic variant (5.7%) with an overall frequency of 9.5%, compared with none in case patients age 30 years and older (P < .001). This high TP53 mutation prevalence in young osteosarcoma cases is statistically significantly greater than the previously reported prevalence of 3% (P = .0024). We identified a novel association between a TP53 rare variant and metastasis at diagnosis of osteosarcoma (rs1800372, odds ratio = 4.27, 95% confidence interval = 1.2 to 15.5, P = .026). Genetic susceptibility to young onset osteosarcoma is distinct from older adult onset osteosarcoma, with a high frequency of LFS-associated and rare exonic TP53 variants.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Rare germline TP53 variants in lung adenocarcinoma
    Parry, Erin Michelle
    Gable, Dustin L.
    Stanley, Susan E.
    Armanios, Mary Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Rare Variants in TP53 and Susceptibility to Neuroblastoma
    Diskin, Sharon J.
    Capasso, Mario
    Diamond, Maura
    Oldridge, Derek A.
    Conkrite, Karina
    Bosse, Kristopher R.
    Russell, Mike R.
    Iolascon, Achille
    Hakonarson, Hakon
    Devoto, Marcella
    Maris, John M.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (04)
  • [3] Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants
    Schwartz, Alison N.
    Hyman, Sophie R.
    Stokes, Samantha M.
    Castillo, Danielle
    Tung, Nadine M.
    Weitzel, Jeffrey N.
    Rana, Huma Q.
    Garber, Judy E.
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 1677 - 1686
  • [4] Pediatric Oncologist Willingness to Offer Germline TP53 Testing in Osteosarcoma
    Shaul, Eliana
    Roth, Michael
    Lo, Yungtai
    Geller, David S.
    Hoang, Bang
    Yang, Rui
    Malkin, David
    Gorlick, Richard
    Gill, Jonathan
    [J]. CANCER, 2018, 124 (06) : 1242 - 1250
  • [5] High prevalence of germline TP53 mutations in young osteosarcoma cases
    Mirabello, Lisa J.
    Yeager, Meredith
    Mai, Phuong L.
    Gastier-Foster, Julie
    Gorlick, Richard
    Khanna, Chand
    Patino-Garcia, Ana
    Sierrasesumaga, Luis
    Lecanda, Fernando
    Andrulis, Irene L.
    Wunder, Jay S.
    Gokgoz, Nalan
    Barkauskas, Donald A.
    Zhang, Xijun
    Vogt, Aurelie
    Jones, Kristine
    Boland, Joseph F.
    Chanock, Stephen J.
    Savage, Sharon A.
    [J]. CANCER RESEARCH, 2015, 75
  • [6] TP53 variants and susceptibility to ovarian cancer in poland
    Garcia-Closas, Montserrat
    Burdett, Laurie
    Brinton, Louise
    Lissowska, Jolanta
    Sherman, Mark
    Yeager, Meredith
    Szeszenia-Dabrowska, Neonila
    Peplonska, Beata
    Welch, Robert
    Mikolajczak, Alicja Bardin
    Zatonski, Witold
    Qi, Ying
    Chanock, Stephen
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [7] Functional characterization of novel germline TP53 variants in Swedish families
    Kharaziha, Pedram
    Ceder, Sophia
    Axell, Olga
    Krall, Moritz
    Fotouhi, Omid
    Bohm, Stefanie
    Lain, Sonia
    Borg, Ake
    Larsson, Catharina
    Wiman, Klas G.
    Tham, Emma
    Bajalica-Lagercrantz, Svetlana
    [J]. CLINICAL GENETICS, 2019, 96 (03) : 216 - 225
  • [8] Concern regarding classification of germline TP53 variants as likely pathogenic
    Evans, D. Gareth
    Turnbull, Clare
    Woodward, Emma R.
    [J]. HUMAN MUTATION, 2019, 40 (06) : 828 - 831
  • [9] Emerging insights into ethnic-specific TP53 germline variants
    Fischer, Nicholas W.
    Ma, Yu-Heng Vivian
    Gariepy, Jean
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (10) : 1145 - 1156
  • [10] Germline TP53 pathogenic variants and breast cancer: A narrative review
    Blondeaux, Eva
    Arecco, Luca
    Punie, Kevin
    Graffeo, Rossella
    Toss, Angela
    De Angelis, Carmine
    Trevisan, Lucia
    Buzzatti, Giulia
    Linn, Sabine C.
    Dubsky, Peter
    Cruellas, Mara
    Partridge, Ann H.
    Balman, Judith
    Paluch-Shimon, Shani
    Lambertini, Matteo
    [J]. CANCER TREATMENT REVIEWS, 2023, 114